6-[18F]fluorometaraminol. A radiotracer for in vivo mapping of adrenergic nerves of the heart
摘要:
The false neurotransmitter metaraminol has been 18F labeled and evaluated as a possible heart imaging agent on the basis of its selective accumulation in adrenergic nerves. Reaction of 6-(acetoxymercurio)-N-t-BOC-metaraminol with acetyl hypofluorite followed by removal of the BOC group provides a regiospecific synthesis of 6-fluorometaraminol (4). Use of acetyl hypo[18F]fluorite gives [18F]-4 in 60 min in 20-42% radiochemical yield. Systemic blockade of the neuronal uptake-1 carrier with desmethylimipramine or systemic destruction of the adrenergic nerves with 6-hydroxydopamine lowers [18F]-4 accumulation greater than or equal to 85% in all four regions of the rat heart. These preliminary findings suggest that [18F]-4 could be used to assess neuronal damage in various heart diseases by positron emission tomography.
Object of the invention is a process for the preparation of Metaraminol and the salts thereof, in particular its pharmaceutically acceptable salts, especially Metaraminol bi-L-tartrate. Object of the invention is also the use of a novel catalyst and a novel ligand for the synthesis of Metaraminol and its salts.
COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS
申请人:JENKINS Thomas E.
公开号:US20120232066A1
公开(公告)日:2012-09-13
The present disclosure provides a composition comprising a GABA
A
agonist and a GI enzyme inhibitor. The present disclosure also provides a composition comprising (a) a GI enzyme inhibitor and (b) a first drug that interacts with a second drug to produce an adverse effect when the second drug is co-ingested as a GI enzyme-cleavable prodrug with the first drug. Such an interaction can be additive or synergistic.
Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes
申请人:3-Dimensional Pharmaceuticals, Inc.
公开号:US20030105111A1
公开(公告)日:2003-06-05
The present invention is directed to a compound of Formula I:
1
wherein A, R
1
, and R
2
are defined herein. The present invention is also directed to compositions comprising compounds of Formula I, methods of using compounds of Formula I, and methods of making compounds of Formula I.